Improving Provision of Care for Long-term Survivors of Lymphoma

The progressive improvement of lymphoma therapies has led to a significant prolongation of patient survival and life expectancy. However, lymphoma survivors are at high risk of experiencing a range of early and late adverse effects associated with the extent of treatment exposure. Among these, second malignancies and cardiopulmonary diseases can be fatal, and neurocognitive dysfunction, endocrinopathy, muscle atrophy, and persistent fatigue can affect patients' quality of life for decades after treatment.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 16, 2017 Category: Hematology Authors: Sabino Ciavarella, Carla Minoia, Angela Maria Quinto, Stefano Oliva, Santa Carbonara, Claudia Cormio, Maria Christina Cox, Elena Bravo, Filippo Santoro, Mariarosaria Napolitano, Michele Spina, Giacomo Loseto, Attilio Guarini Tags: Review Source Type: research